S&P 500

5.127,79

1,26%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
ChemoCentryx Inc (CCXI)
ChemoCentryx Inc (CCXI) Notícias

CCXI

ChemoCentryx (CCXI)

ChemoCentryx Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:CCXI

1 2 3 4 5 6 7 8 9 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
24/10/2022	20:14	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:CCXI	ChemoCentryx Inc
20/10/2022	10:28	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:CCXI	ChemoCentryx Inc
20/10/2022	10:27	Edgar (US Regulatory)	Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)	NASDAQ:CCXI	ChemoCentryx Inc
20/10/2022	10:20	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CCXI	ChemoCentryx Inc
20/10/2022	10:05	PR Newswire (US)	AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX	NASDAQ:CCXI	ChemoCentryx Inc
20/10/2022	09:41	Edgar (US Regulatory)	Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)	NASDAQ:CCXI	ChemoCentryx Inc
17/10/2022	09:30	GlobeNewswire Inc.	ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings	NASDAQ:CCXI	ChemoCentryx Inc
07/10/2022	17:36	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:CCXI	ChemoCentryx Inc
05/10/2022	09:30	GlobeNewswire Inc.	ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting	NASDAQ:CCXI	ChemoCentryx Inc
14/09/2022	18:32	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (definitive) (defm14a)	NASDAQ:CCXI	ChemoCentryx Inc
12/09/2022	12:14	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:CCXI	ChemoCentryx Inc
31/08/2022	18:08	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (preliminary) (prem14a)	NASDAQ:CCXI	ChemoCentryx Inc
24/08/2022	09:30	GlobeNewswire Inc.	ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences	NASDAQ:CCXI	ChemoCentryx Inc
09/08/2022	10:40	TipRanks	Analysts Offer Insights on Healthcare Companies: ChemoCentryx (CCXI) and ATI Physical Therapy (ATIP)	NASDAQ:CCXI	ChemoCentryx Inc
09/08/2022	09:30	GlobeNewswire Inc.	ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call	NASDAQ:CCXI	ChemoCentryx Inc
04/08/2022	10:12	Dow Jones News	ChemoCentryx Shares Soar Premarket on Amgen Takeover Deal	NASDAQ:CCXI	ChemoCentryx Inc
04/08/2022	09:00	PR Newswire (US)	AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH	NASDAQ:CCXI	ChemoCentryx Inc
02/08/2022	17:05	GlobeNewswire Inc.	ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022	NASDAQ:CCXI	ChemoCentryx Inc
05/07/2022	09:30	GlobeNewswire Inc.	ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director	NASDAQ:CCXI	ChemoCentryx Inc
06/06/2022	11:15	TipRanks	H.C. Wainwright Sticks to Its Buy Rating for ChemoCentryx (CCXI)	NASDAQ:CCXI	ChemoCentryx Inc
06/06/2022	09:30	GlobeNewswire Inc.	ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:CCXI	ChemoCentryx Inc
31/05/2022	17:05	GlobeNewswire Inc.	ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences	NASDAQ:CCXI	ChemoCentryx Inc
31/05/2022	09:30	GlobeNewswire Inc.	ChemoCentryx Announces Changes to its Board of Directors	NASDAQ:CCXI	ChemoCentryx Inc
22/05/2022	05:46	TipRanks	Can ChemoCentryx Control Challenging Capital Complications?	NASDAQ:CCXI	ChemoCentryx Inc
18/05/2022	09:30	GlobeNewswire Inc.	ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa	NASDAQ:CCXI	ChemoCentryx Inc
16/05/2022	09:30	GlobeNewswire Inc.	ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference	NASDAQ:CCXI	ChemoCentryx Inc
11/05/2022	09:30	GlobeNewswire Inc.	ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis	NASDAQ:CCXI	ChemoCentryx Inc
10/05/2022	17:35	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:CCXI	ChemoCentryx Inc
09/05/2022	04:26	TipRanks	Raymond James Maintains Their Buy Rating on ChemoCentryx (CCXI)	NASDAQ:CCXI	ChemoCentryx Inc
08/05/2022	23:18	TipRanks	ChemoCentryx (CCXI) Receives a Buy from Stifel Nicolaus	NASDAQ:CCXI	ChemoCentryx Inc